Other Mutations: EGFR

NCT05241873: Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Phase 1; Patients must have documented EGFR Exon 20 insertion mutation
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with tumors that express other known driver alterations (including, but not limited to ROS, BRAF V600E, ALK, RET, HER2, MET, KRAS, NTRK1/2/3, or EGFR C797X mutation)
https://ClinicalTrials.gov/show/NCT05241873

NCT05144698: RAPA-201 Therapy of Solid Tumors

NCT05144698
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF, ALK, BRCA+, EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have exposure to an anti-PD-(L)1 therapeutic monoclonal antibody therapeutic in the most recent line of prior therapy (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
Exclusions: Patients with cancer metastasis to the central nervous system, unless adequately treated
https://ClinicalTrials.gov/show/NCT05144698

Up ↑